YOU MAY BE ENTITLED TO COMPENSATION AND DAMAGES FOR YOUR INJURIES – WE ARE AVAILABLE TO ASSIST YOU IN YOUR RECOVERY
Xolair Can Increase the Risk of Severe Heart Problems, Brain and Blood Vessel Problems and Cancer
According to class action lawsuits filed against Genentech and Novartis, the makers and marketers of Xolair, the companies knew of the serious risks of the medication but failed to warn the public.
If you or a family member has taken Xolair and have been injured, you may be entitled to compensation.
- Our firm is vigorously pursuing this matter.
- Our clients have received millions of dollars in lawsuits involving defective drugs.
- No Charge or Obligation for Our Experienced Attorney Review
CONTACT US NOW! Do Not Delay As The Applicable Statute Of Limitations May Result In A Complete Bar To Your Claim Regardless Of Its
Xolair (omalizumab) was approved by the FDA in 2003 to treat patients 12 years and older with moderate to severe asthma caused by allergens also called allergic asthma. Xolair is an injection which helps reduce the number of asthma attacks for those who are still suffering from asthma symptoms even though they are taking inhaled steroids. Xolair is also approved for use with those who suffer from chronic hives and are not helped by taking H1 antihistamine treatments.
The possible side effects of Xolair include:
- Heart attack
- Transient ischemic attacks (TIAs)
- Chest pain
- Pulmonary hypertension
- Blood clots in lungs and veins
In 2009, the FDA required the makers of Xolair, Grenentech, Inc., to perform a 5-year study regarding the safety of the drug. Due to the data from this study, the FDA ruled in September 2014 that new warnings on Xolair package inserts and prescribing information need to be added detailing the risks of serious complications caused by the drug’s side effects. During the same time, the FDA issued a drug safety warning that Xolair’s side effects can cause the serious complications listed above. The new safety warnings join a black box warning added in 2007 regarding the risk of severe and life threatening allergic reaction called anaphylaxis.